In addition to SPD, metabolic tumor volume, LDH and target (CD19) expression, measurements of tumor immune contexture using Immunoscore, IS21 (ref. 36), B cell, as well as stromal and immunosuppressive gene signatures, are emerging as important and interrelated determinants of durable responses to axi-cel intervention. The gene discussed is CD19; the disease is neoplasm.